Expiration date: 04/2025
Release form and composition:
Powder for preparation of oral solution from light orange to orange in color, with white and orange inclusions, with the orange taste.
1 sachet (5 g) contsins:
paracetamol 750 mg
caffeine 30 mg
feniramina maleate 20 mg
fenilafrina hydrochloride 10 mg
Excipients: citric acid anhydrous, sodium saccharin, sodium citrate, sucrose, colorant sunset yellow FCF, orange flavouring substance.
5 g sachet (5) - packs of cardboard.
5 g sachet (10) - packs of cardboard.
5 g sachet (25) - packs of cardboard.
5 g sachet (50) - packs of cardboard.
5 g sachet (100) - packs of cardboard.
Powder for preparation of oral solution from light yellow to yellow color, with white and yellow patches, with a taste of lemon.
1 sachet (5 g) contsins:
paracetamol 750 mg
caffeine 30 mg
feniramina maleate 20 mg
fenilafrina hydrochloride 10 mg
Excipients: citric acid anhydrous, sodium saccharin, sodium citrate, sucrose, colorant quinoline yellow, lemon flavouring substance.
5 g sachet (5) - packs of cardboard.
5 g sachet (10) - packs of cardboard.
5 g sachet (25) - packs of cardboard.
5 g sachet (50) - packs of cardboard.
5 g sachet (100) - packs of cardboard.
Powder for preparation of oral solution from pink to pinkish-red in color, with white and red inclusions, with flavors of black currant.
1 sachet (5 g) contsins:
paracetamol 750 mg
caffeine 30 mg
feniramina maleate 20 mg
fenilafrina hydrochloride 10 mg
Excipients: citric acid anhydrous, sodium saccharin, sodium citrate, sucrose, carmoisine dye, a fruit flavouring substance, flavouring substance raspberry, blackcurrant flavouring substance.
5 g sachet (5) - packs of cardboard.
5 g sachet (10) - packs of cardboard.
5 g sachet (25) - packs of cardboard.
5 g sachet (50) - packs of cardboard.
5 g sachet (100) - packs of cardboard.
Pharmacological action:
Combined medication used for colds.
Paracetamol - analgesic-antipyretic, reduces pain, observed for colds - sore throat, headache, muscle and joint pain, lowers high body temperature.
Phenylephrine - sympathomimetic, has a vasoconstrictor action on peripheral blood vessels, reduces swelling and hyperemia mucous membranes of the upper respiratory tract and sinuses.
Feniramin – blocker of histamine H1-receptors, has anti-allergic effect: eliminates itching of the skin (including eyes, nose), swelling and hyperemia mucous membranes cavity of the nose, nasopharynx and sinuses, reduces the phenomenon of exudation.
Caffeine has a stimulating effect on the Central nervous system, which reduces fatigue and sleepiness and to boost mental and physical performance.
Pharmacokinetics:
Data on the pharmacokinetics of the drug Rinzasip not provided.
Indications:
Symptomatic therapy (to reduce pain, fever and rinorea):
flu
— SARS and other respiratory diseases.
Dosing regimen:
Adults and children over 15 years appoint 1 paketiku 3-4 times/day with intervals between meals at least 4-6 hours Maximum daily dose is 4 sachets. The course of treatment should not exceed 5 days.
The drug is taken 1-2 hours after meals with plenty of liquid.
Contents of 1 sachet dissolved in 1 Cup hot water (stir until dissolved). You can add sugar or honey.
Side effects:
CNS: dizziness, impaired sleep, anxiety, mydriasis, increased intraocular pressure, paralysis of accommodation.
From the side of cardiovascular system: increased blood pressure, tachycardia.
From the digestive system: nausea, epigastric pain, dry mouth, hepatotoxic effects.
With the hematopoietic system: anemia, thrombocytopenia, agranulocytosis, hemolytic anemia, aplastic anemia, methemoglobinemia, pancytopenia.
From the urinary system: urinary retention, nephrotoxicity (papillary necrosis).
Allergic reactions: skin rash, itching, hives, angioedema.
Other: broncho-obstructive syndrome.
Contraindications:
— simultaneous reception tricyclic antidepressants, MAO inhibitors, beta-blockers
— pregnancy
— lactation (breast feeding)
— child and adolescence to 15 years
— simultaneous intake of other drugs, which include the active substances of the medicinal product Rinzasip
— hypersensitivity to paracetamol and other components of the drug.
Be wary appoint drug in patients with severe atherosclerosis of the coronary arteries, arterial hypertension, thyrotoxicosis, pheochromocytoma, patients with diabetes, bronchial asthma, chronic obstructive pulmonary disease, with a deficit glukozo-6-fosfatdegidrogenaza, blood diseases, patients with hereditary hyperbilirubinemia (Gilbert syndrome, Dubin-Johnson and Rotor), and liver and/or kidney failure, angle-closure glaucoma, prostatic hyperplasia.
Pregnancy and lactation:
The drug is contraindicated during pregnancy and lactation (breastfeeding).
Special instructions:
During application of the drug should refrain from alcohol, tranquilizers or anxioliticeski medicines.
You cannot use preparations containing paracetamol.
The patient should be warned to contact doctor if the condition does not improve after 3-5 days of treatment.
Effects on ability to drive vehicles and management mechanisms
During application of the drug should use caution in potentially hazardous activities, require increased attention and psychomotor speed reactions.
Overdose:
Overdose symptoms due to the effects of paracetamol occur while taking the drug in a dose corresponding to 10-15 g of paracetamol.
Symptoms: paleness, anorexia, nausea, vomiting, increase in liver transaminases, gepatonekros, liver failure (increased prothrombin time).
Treatment: gastric lavage, inside - activated carbon symptomatic therapy, the introduction of methionine via 8-9 hours after the overdose and N-acetylcysteine through 12 h.
Drug interactions:
In a joint application Rinzasip enhances the effects of MAO inhibitors, sedative drugs, ethanol.
In a joint application with the drug Rinzasip antidepressants, antiparkinsonian funds, antipsychotic drugs, phenothiazines increase the risk of urinary retention, dry mouth, constipation.
In a joint application of corticosteroids increase the risk of developing glaucoma.
Paracetamol reduces the effectiveness of the same used diuretics.
Tricyclic antidepressants increase adrenomimetic action fenilafrina, appointment with halothane increases the risk of ventricular arrhythmias.
In a joint application Rinzasip reduces the antihypertensive effect guanetidina, which in turn, increases alpha given action fenilafrina.
While the use of Rinzasip with barbiturates, phenytoin, carbamazepine, rifampicin and other inducers of microsomal liver enzymes increase the risk of hepatotoxic action of paracetamol.
Terms and conditions of storage:
The drug should be stored in a dry, inaccessible for children place at temperature not exceeding 25°C. shelf Life - 3 years.
